Vistagen advances PALISADE-4 trial with $61.8M in cash while refining placebo mitigation strategies

Singh reiterated that PALISADE-4 remains on track with previous guidance and that, if successful along with PALISADE-2, the data “may support a potential new drug application submission to the U.S.

OpenAI’s rapid GPT-5.3-Codex model moves beyond simple coding tasks

“Codex-Spark is the first step toward a Codex that works in two complementary modes: real-time collaboration when you want ...